Subscribe free

HPB & Spleen ·

Neoadjuvant chemotherapy, not adjuvant, rescues pancreatic cancer patients with close margins

Patients with close (≤1 mm) margins after pancreatic cancer surgery had worse survival than those with clear margins. Neoadjuvant chemotherapy, but not adjuvant chemotherapy, brought their survival close to that of patients with clear margins.

  • Median overall survival was 15.0 vs 24.0 months for ≤1 mm vs >1 mm margins after upfront resection.
  • Neoadjuvant chemotherapy raised median survival in ≤1 mm patients to 29.4 months, vs 19.6 months with upfront surgery.
  • Retrospective cohort of 110 patients, with an external CT radiomics model (AUC 0.72–0.77) to predict close margins before surgery.

This applies to pancreatic head cancer patients at high risk of close margins, identified by CT radiomics. It is a retrospective comparison, so it supports selecting patients for neoadjuvant chemotherapy, not a general switch to it.

Journal Article by Li M, Lin Y (…) Ke N et 8 al. in J Surg Oncol

© 2026 Wiley Periodicals LLC.

read the whole article in J Surg Oncol

open it in PubMed

Summaries are written to help you decide what to read. They do not replace the full paper.

Free · 5 minutes a day

Get every new paper in HPB & Spleen.

Plus the Daily Selection: the five most relevant papers of the day, each cut to its key points.

Specialty newsletters: every new paper in your field, as a list of titles linked to the source. Daily Selection: the five that matter, cut to their key points.

FreeNo spamOne-click unsubscribe

More in HPB & Spleen

The latest stitches

All papers in HPB & Spleen →